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Proteasomemportant role in regulating numerous functions in vertebrates. Several pathways
that negatively regulate the magnitude and duration of its signaling (including expression of tyrosine
phosphatases, SOCS and PIAS proteins) are shared between signaling induced by growth hormone itself and
by other cytokines. Here we overview downregulation of the growth hormone receptor as the most speciﬁc
and potent mechanism of restricting cellular responses to growth hormone and analyze the role of several
proteolytic systems and, speciﬁcally, ubiquitin-dependent pathways in this regulation.
© 2008 Elsevier B.V. All rights reserved.1. Growth hormone actions and regulation of receptor abundance
Growth hormone (GH) is a 22,000 Da peptide hormone derived
mainly from the anterior pituitary gland that is critical in promotion of
growth and regulation of metabolism and energy balance andmay have
a role in longevity in humans and other vertebrates [1,2]. Clinically,
disruptions in GH action are most evident when either GH levels are
either too high or too low. GH excess found in the setting of a GH-
secreting pituitary adenoma yields the syndrome of acromegalywith its
characteristic connective tissue and bony overgrowth, visceromegaly,
and insulin resistance [3]; if present prior to closure of the epiphyseal
growth plates, gigantism results. Conversely, GH deﬁciency in childhood
yields shortness of stature, altered fat distribution, and a tendency to
hypoglycemia [4]. In addition to these scenarios, an emerging ex-
perimental literature suggests potential roles for both pituitary-derived
GH and autocrine/paracrine GH produced in extra-pituitary sites in
potentiating or aberrantly promoting certain cancers [5–9].
Observations in patients with GH resistance (Laron syndrome) [10]
and analysis of mice with targeted deletion of the GH receptor (GHR)
[11] indicate that the in vivo biological actions of GH are transduced by
the GHR, a member of the cytokine receptor superfamily [12,13].
GHR is a widely distributed ∼620 residue type 1 single membrane-irmingham, 1530 3rd Avenue
: +1 205 934 9877; fax: +1 205
l rights reserved.spanning glycoprotein, expressed in many species, that likely exists
as a dimer at the cell surface where it binds GH in its extracellular
domain and signals by regulated interaction of its ∼350 residue
intracellular domain with signaling molecules [13–16]. The GHR
couples physically and functionally the Janus kinase, JAK2, which is a
cytoplasmic tyrosine kinase that is also utilized by other cytokine
receptor family members [17,18]. JAK2 associates non-covalently with
the dimerized GHR during its biogenesis and at the cell surface via the
receptor's proline-rich perimembranous intracellular domain Box 1
element and the N-terminal FERM domain of JAK2 [19–25]. GH-
triggered activation of JAK2 causes GHR and JAK2 tyrosine phosphor-
ylation and induces signaling systems including STATs (most notably
STAT5b), ERKs, and PI3-kinase [14–16] (Fig. 1). GH-induced STAT5b
activation requires receptor tyrosine phosphorylation and promotes
gene transcription (eg., IGF-1, acid-labile subunit (ALS) of the IGF
binding protein complex, SOCS proteins, hepatic P450 enzymes, and
serine protease inhibitor 2.1 (Spi2.1) [26–36]). Unlike STAT5b, GH-
induced ERK and PI3K activation does not require the entire GHR
cytoplasmic domain, but only JAK2 coupling [21–23,37–39]. ERK
activity is critical for GH-induced c-fos transcription [40], enhances
GH-stimulated proliferation [41], and mediates crosstalk with EGF
signaling [42–44]. GH-induced PI3K activity is implicated in anti-
apoptosis and/or proliferation and likely contributes to GH-induced
ERK, p70 S6 kinase, and phosphodiesterase activity [40,41,45–49].
GH sensitivity is substantially affected by the abundance of GHR
available for ligand engagement at particular target cells and tissues.
Surface GHR availability is regulated at several levels, including
Fig. 1. GH signaling pathways. GH binds to the cell surface dimerized GHR, causing JAK2 activation and activation of downstream pathways, including STAT5, PI3-kinase, and ERK
pathways.
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tional and post-transcriptional GHR regulation have been reviewed
extensively [50–52] and will not be further dealt with in this review.
Post-translational regulation of GHR abundance is exerted at the levels
of receptor biosynthesis and trafﬁcking to the cell surface, stability and
constitutive (non-GH-dependent) downregulation of the surface
receptor, metalloprotease-mediated GHR processing, and GH-induced
GHR downregulation. Elements of each of these processes are
impacted upon by the ubiquitin–proteasome system and each will be
further discussed below in this context.
The ubiquitin–proteasome system is critical in maintenance of
cellular physiology and the health of humans and other organisms.
With regard to GH action and the GH axis, there are as yet no examples
of speciﬁc disruptions of the ubiqutin–proteasome system that
themselves account for disease states, but two interesting examples
of mutational alteration of GH signaling elements that affect protein
turnover in disease states have recently been deﬁned that may relate
to this important system.
One of these pertains to the syndrome of acromegaly. As alluded to
above, the basis for this syndrome is in almost all instances a
somatotroph adenoma that secretes excessive GH in a dysregulated
fashion. Nearly twenty years ago, investigators uncovered a pituitary-
speciﬁc activating mutation of the G-protein that couples to the GH
releasing hormone receptor, thereby underlying the pathogenesis of
many so-called “densely granulated” GH-secreting anterior pituitary
adenomas [53–56]. A recent analysis of pituitary tumor specimens
also demonstrated that nearly one-half of densely granulated tumors
harbored such an activating mutation, but none were found in any of
the fourteen “sparsely granulated” GH-secreting tumors examined
[57]. Interestingly, six (43%) of these sparsely granulated tumors
harbored a heterozygous mutation of the GHR that predicts a change
of His to Leu in codon 49 of the extracellular domain; none of the
densely granulated tumors exhibited any mutations of GHR. Func-
tional analysis of a site-directed H49L mutant GHR in a reconstitution
system (more below) revealed that this mutant receptor exhibited
altered post-translational processing with accumulation of the
precursor form of the receptor at the expense of the mature form.
Notably, however, the mutant precursor was markedly longer-lived
than the wild-type precursor and the mature form of the mutant that
found its way to the cell surface displayed decreased GH bindingcapacity and diminished GH signaling [57]. This work is important in
that it suggests an autofeedback loop of GH on the anterior pituitary
somatotrophs via the somatotroph GHR, the disruption of which leads
to hypersecretion of GH; this is a novel concept in pituitary-GH phy-
siology. Furthermore, it will be important to determine if the buildup
of the precursor (which, as seen below, is normally either rapidly
processed to the mature form or undergoes endoplasmic reticulum-
associated degradation) is due to or causative of disruption of the
ubiquitin–proteasome system in these cells.
Another recent example of alteration of a GH signaling component
relating to the function of the ubiquitin–proteasome system derives
from investigation of a naturally-occurring mutation of STAT 5b
[58,59]. Targeted deletion of Stat 5b in mice leads to disruption of key
GH-dependent growth and metabolic functions [34]. Kofoed, et al.
[59] described a young woman with a homozygous mutation of the
Stat 5b gene that predicts a change of alanine to proline at residue 630
in the phosphotyrosine-binding SH2 domain. This patient had short-
ness of stature and evidenced clinical and biochemical GH insensiti-
vity. When the mutation was studied in the context of cellular
reconstitution experiments [58], this A630P Stat 5b mutant was found
to have a dramatically shortened half-life and failed to undergo
activation in response to GH. Furthermore, the mutant displayed
markedly enhanced aggregation and formed cytoplasmic inclusions.
Perhaps most notably, expression of the mutant Stat 5b conferred
defective proteasome function on the cells in which it was expressed,
such that other proteins normally degraded by the proteasome were
less susceptible to this activity. Thus, mutation of this critical GH signal
transducing element not only caused GH resistance, but also disrupted
proteasomal function because of its aberrant folding.
2. Trafﬁcking of the newly synthesized GHR: roles of JAK2 and the
proteasome
The GHR is synthesized as a non-glycosylated nascent precursor
that is transported from the endoplasmic reticulum (ER) to the Golgi
apparatus. It is now clear that GHR dimerizes in the ER early in the
process of biogenesis, thus accounting for the receptor dimers detected
at the cell surface even in the absence of GH engagement [19,60,61].
Recent studies undertook to determine the role, if any, that association
of theGHRwith JAK2has on the receptor's trafﬁcking to the cell surface
787S.J. Frank, S.Y. Fuchs / Biochimica et Biophysica Acta 1782 (2008) 785–794[62,63]. These studies yielded not only an appreciation of JAK2's role as
a potential chaperone early in the biosynthetic pathway, but also
revealed an interesting role for the proteasome with regard to GHR
trafﬁcking.
As for many other surface glycoprotein receptors, the progress of
GHR biogenesis and trafﬁcking can be tracked by monitoring
biochemically the degree and type of glycosylation it undergoes. In
the process of transport through the Golgi, the GHR acquires carbo-
hydrate in a characteristic fashion, in which high-mannose sugars
added in the ER are ultimately removed during the transition from the
early to late Golgi to yield the mature glycosylated GHR that populates
the cell surface. This process can be assessed by determining the
receptor's sensitivity to in vitro deglycosylation by endoglycosidase
H (endoH). Mature GHR is endoglycosidase H (endoH)-resistant while
the high-mannose GHR precursor is sensitive to deglycosylation by
endoH [25,30,62,64,65]. Using this feature, as well as a robust cellular
stable reconstitution system inwhich GHRwas expressed either in the
presence or absence of JAK2 and immunoblotting and pulse-chase
metabolic labeling techniques, it was ﬁrst observed that although JAK2
is not required for detectable surface GHR expression, cells expressing
JAK2 exhibited enhanced surface GHR abundance and an increased
mature:precursor GHR ratio compared with JAK2-deﬁcient cells,
suggesting that JAK2 fosters GHR maturation [25,62].
Furthermore, in cells that lack JAK2, a GHR fragment was detected
with antibodies to the receptor intracellular domain, but not the
extracellular domain [63,66]. The abundance of this fragment and the
steady-state level of GHR precursor relative to the mature form were
dramatically lessened by expression of wild-type JAK2 or JAK2
mutants that were capable of interacting with GHR, independent of
whether such mutants possessed tyrosine kinase activity. Similarly,
cells that harbored a GHRmutant that lacks the ability to interact with
JAK2 (by virtue of mutation of the receptor Box 1 region) also
manifested the same intracellular domain-containing GHR fragment
and a decreased mature:precursor GHR ratio, independent of whether
JAK2 was expressed. These data point to the ability of GHR to associate
with JAK2 as enabling efﬁcient receptor maturation and indicate that
the presence of the intracellular domain-containing fragment of the
receptor reﬂects inefﬁciency in this process.
Further studies focused on factors that affected the level of the
intracellular domain-containing fragment in JAK2-deﬁcient cells [63].
Notably, treatment of these cells with a proteasome inhibitor
(lactacystin), but not two separate lysosome inhibitors, dramatically
decreased the level of this receptor fragment and this was accom-
panied by decreased precursor GHR and increased mature GHRFig. 2. JAK2 association affects endoplasmic reticulum to cell surface GHR trafﬁcking. In cell
Golgi, matures, and reaches the cell surface efﬁciently. In cells lacking JAK2 orwith GHRmolec
degradation (ERAD) and inefﬁciently matures and trafﬁcs to the cell surface.abundance. When brefeldin A (BFA) was used to disrupt ER-to-Golgi
transport, the abundance of the intracellular domain fragment was
also reduced; washout of BFA allowed regeneration of the fragment
along with the GHR precursor. Interestingly, washout of BFA in the
presence of cycloheximide (to prevent new protein synthesis) blocked
reappearance of both the intracellular domain fragment and the
precursor GHR, but washout of BFA in the presence of lactacystin
prevented reappearance only of the intracellular domain fragment.
Thus, the intracellular domain fragment appeared to derive from the
precursor GHR in a proteasome-dependent fashion.
The data in these studies suggest that in cells that lack JAK2
the nascent precursor GHR is a target for endoplasmic reticulum-
associated degradation (ERAD) and represent the ﬁrst example of
ERAD-associated cleavage of a cytokine receptor family member that
stems from a lack of its cognate JAK (Fig. 2). ERAD is a process whereby
proteins that fail to fold properly or otherwise fail quality control
mechanisms in the ER undergo retrotranslocation and proteasomal
degradation in the cytosol [67–69]. JAK2, by virtue of its association
with the GHR, rather than via its kinase activity, apparently
“chaperones” the dimerized precursor so as to avoid quality control
and proceed with efﬁcient processing to mature GHR in the secretory
pathway. How does JAK2 exert this chaperone effect? Multiple pos-
sibilities exist, including the notion that a receptor region that might
otherwise be seen as defective or unfolded to the quality control
apparatus is hidden by JAK2 binding. In a similar fashion, JAK2 binding
might allosterically alter a GHR site outside of the region that interacts
with JAK2 to make that site appear less defective. Unraveling of such
possibilities awaits further investigation.
Stabilizing effects on the cell surface levels of respective cytokine
receptors have been shown for all members of JAK family including
TYK2 (for IFNAR1 [70,71] and thrombopoietin receptor (TpoR) [72]),
JAK1 (for oncostatin M receptor [73,74] and IL-9Rα, and IL-2Rβ [72]
and Fuchs, et al, unpublished data), JAK2 (for TPOR [72], erythropoie-
tin receptor [75], and GHR [62]) and JAK3 (for the common gamma
chain of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptor complexes [76]).
Little is known about the mechanisms by which different JAK family
members increase the cell surface levels of different receptor chain;
models proposed so far include a chaperone-like assistance in re-
ceptor folding, maturation and delivery to the cell surface, inhibition
of basal endocytosis and/or post-internalization sorting into the late
endosomes/lysosomes, as well as protection from proteasome-me-
diated degradation.
A novel aspect of the work on JAK2 and GHR biosynthesis that
extends broadly into the arena of ERAD and proteasome function iss harboring GHR and JAK2 molecules that can associate, GHR moves from the ER to the
ules that cannot associatewith JAK2, GHR undergoes endoplasmic reticulum-associated
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discrete intracellular domain-containing receptor fragment that is
stable enough to be detected by immunoblotting. Assuming that the
proteasome (rather than a separate proteasome-dependent protease)
directly catalyzes GHR ERAD under JAK2-deﬁcient circumstances,
such an apparently discrete cleavage is somewhat unusual. Protea-
somal degradation is usually thought to involve the threading of
target proteins through the proteasome complex's gated substrate
channel. Relatively few instances of incomplete or discrete cleavage
by the proteasome have been described. Examples include the
incomplete cleavage of NF-κB p105 yielding the p50 subunit due to
the presence of a “processing stop signal” [77,78] and the endopro-
teolytic cleavage of certain fusion proteins [79]. Whether either of
these mechanisms is in play to explain the ERAD-generated, pro-
teasome-dependent production of the intracellular domain-contain-
ing GHR is as yet unknown.
3. Proteolysis of the GHR: roles of TACE, γ-secretase, and the
proteasome
Over the last decade, it has become appreciated that GHR, like
some other surface receptors, is a target for regulated sequential
proteolysis, the ﬁrst step of which (“α-secretase cleavage”) occurs in
the proximal extracellular domain stem region 8–9 residues (depend-
ing on species) outside the plasma membrane [65,80,81]. This α-
secretase cleavage results in loss of full-length GHR, appearance of a
cell-associated transmembrane domain (TMD)/intracellular domain
(ICD)-containing receptor fragment (the “remnant”), and a soluble
GHR extracellular domain (ECD) (called GH binding protein (GHBP), in
correspondence with the high afﬁnity GH binding protein that
circulates in many species, including humans [82,83]). GHR α-
secretase cleavage is constitutive, but can be further induced in va-
rious cell types by a protein kinase C activator (the phorbol ester,
PMA), platelet-derived growth factor (PDGF), or serum [65,80,81,84–
87]. This cleavage is catalyzed mainly by the extracellular domain of
the transmembrane metalloprotease, TACE (tumor necrosis factor-α
converting enzyme; ADAM-17) [66,88]. Importantly, inducible α-
secretase cleavage likely regulates GH sensitivity; that is, GH-induced
signaling is dampened after cells are exposed to stimuli that promote
GHR α-secretase cleavage, but not in the presence of metalloprotease
inhibitors or if noncleavable receptor mutants are expressed, sug-Fig. 3. GHR undergoes sequential TACE and gamma-secretase cleavage. Surface GHR undergoe
a process called “alpha-secretase” cleavage. This yields the shed GHBP and the GHR remnan
stub (soluble intracellular domain), which localizes to the nucleus, where it may affect gengesting that metalloproteolysis modulates GH responsiveness in part
by regulating surface GHR levels [65,83,84]. Further, recent in vivo
experiments indicate that administration of bacterial endotoxin leads
to downregulation of hepatic GHR abundance and hepatic insensitiv-
ity to GH at least in part by inducing receptor proteolysis, suggesting
that this may constitute a physiologically-relevant mechanism of
regulation of GH action [89]. Notably, GH itself does not promote GHR
α-secretase cleavage; indeed, GH inhibits subsequent GHR proteo-
lysis, apparently by altering GHR conformation, rather than by causing
signaling [66].
Recent studies have shown that the α-secretase-generated GHR
TMD/ICD remnant is further cleaved by an enzyme activity termed
“γ-secretase” within the TMD, which liberates the ICD, a protein
termed the “GHR stub” [87]. γ-secretase consists of four molecules,
including presenilin, which forms the aspartyl protease core and
facilitates a process known as regulated intramembrane proteolysis
(RIP) [90]. The GHR stub was detected by immunoblotting most
readily when cells were pretreated with either of the proteasome
inhibitors, lactacystin or epoxomicin [87], but such treatment had no
effect on either the formation or degradation of the remnant from
which the stub derives. Thus, the stub is selectively degraded in a
proteasome-dependent fashion. Furthermore, the stub can be detec-
ted in both the cytosol and the nucleus [87]. The data are consistent
with the notion that inducible α-secretase cleavage generates rem-
nant, which is converted to stub by γ-secretase. The stub is labile and
can accumulate in the nucleus; proteasome inhibition prevents stub
degradation (Fig. 3).
The two-step α-/γ-secretase GHR processing is analogous to that
seen for amyloid precursor protein, Notch, and others; in those
systems, nuclear-localized ICD fragments affect gene expression [90].
It is not yet known whether the GHR stub also regulates gene
expression. However, as α-/γ-secretase GHR processing is inhibited,
rather than stimulated, by GH, such GHR-mediated gene expression
could constitute a unique mechanism by which GH may affect gene
expression; that is, by negatively regulating stub formation, rather
than by promoting via GHR signaling the activation of STAT5 and
STAT5-mediated gene transcription, for example. If such an alternative
pathway of GH-modulated gene expression does exist, it will likely be
modulated by factors that affect proteasome activity. Future studies
will likely address whether the stub indeed associates with chroma-
tin/DNA and, if so, which genes might be regulated by the stub.s constitutive and inducible cleavage in the extracellular domain stem region by TACE in
t. Remnant is then cleaved by gamma-secretase within the membrane to yield the GHR
e expression.
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Once at the cell surface, the GHR could, in principle, achieve several
fates. If engaged by GH, signaling is triggered and the receptor
undergoes ligand-dependent downregulation (more below). However,
in the natural milieu, GH is released from the pituitary gland in a
pulsatile fashion such that GH levels are quite low in periods between
pulses. Thus, it is critical to understand factors that govern GHR abun-
dance independent of GH. It is believed that mature GHRs are cleared
from the cell surface by constitutive or inducible proteolytic shedding
and by constitutive downregulation. GHR proteolysis was discussed
above. Recent work has revealed important features relating to
constitutive downregulation and has, in particular, focused on effects
of JAK2 on this process.
Elegant work over the past decade, emanating mainly from the
Strous laboratory and performed largely in one cell system (a stably
GHR-transfected temperature-sensitive Chinese hamster lung ﬁbroblast
that has a thermolabile ubiquitin activating enzyme E1), has suggested
that constitutive (and GH-induced) GHR endocytosis requires an intact
ubiquitin–proteasome system; an important conclusion drawn was
that, although GHR is ubiquitinated, this ubiquitination is not necessary
for its endocytosis [91–93] (more below). The so-called ubiquitin-
dependent endocytosis (UbE) motif, a conserved ten residue region in
the proximal third of the receptor's cytoplasmic domain, is believed to
be necessary for efﬁcient GHR endocytosis [94–97]. Furthermore, these
studies suggest that even though an intact ubiquitin–proteasome
system is required, constitutive GHR endocytosis results in lysosomal,
rather than proteasomal, degradation.
As above, JAK2 affects the fate of the cell surface GHR and in cells
lacking JAK2, the ratio of mature (cell surface):precursor GHR was
substantially reduced in comparison to JAK2-replete cells [25,62]. This
ﬁnding is partly explained by the chaperone effect of JAK2 during GHR
biogenesis [63]. However, notable JAK2-dependent differences in the
constitutive fate of mature GHRs are found as well [62]. In the context
of a stable reconstitution system, the half-life (t1/2) of the receptor was
estimated by anti-GHR immunoblotting after 0–4 h of treatment with
cycloheximide (CHX) to inhibit new protein synthesis. The results of
such a “CHX chase” assay indicated that the precursor GHR abundance
dropped precipitously and to a similar degree with increasing
duration of CHX treatment both in cells that did or did not express
JAK2. For the mature receptor, however, there was a dramatic effect of
JAK2. As measured by this assay, the GHR t1/2 increased from roughly
1 hr in cells that lack JAK2 to roughly 4 h in cells expressing JAK2 [62].Fig. 4. JAK2 association affects the constitutive (GH-independent) fate of surface GHR. In cells
a low constitutive rate and its half-life is long. In cells that lack JAK2 or have GHR and JAK2 m
and exhibits a short half-life.Thus, in the absence of GH, it appears that, in addition to its role in
shepherding the GHR through the secretory pathway and lessening
the degree to which it is targeted for ERAD, JAK2 also extends the
receptor's presence at or near the cell surface, presumably by in-
terfering with constitutively active cellular machinery that functions
to internalize and downregulate the receptor (Fig. 4). Notably, this
latter effect has also been detected for another JAK family member,
TYK2, with regard to its associated type I interferon-α receptor
(IFNAR1) [71], but not for some other cytokine receptor/JAKs, in-
cluding the erythropoietin receptor/JAK2 [75] and the oncostatin M
receptor/JAK1 [73].
The degradative pathways operative in conferring the rapid
downregulation of mature (presumably cell surface) GHR in cells
lacking JAK2 were also studied [62]. In particular, both a proteasome
inhibitor (clasto-lactacystin β-lactone, an active analog of lactacystin)
and lysosome inhibitors (ammonium chloride and chloroquine) were
tested and inhibition of each pathway similarly prevented loss of the
mature GHR upon CHX treatment in the cells that lack JAK2, but no
effect was seen in cells that express JAK2 (as the mature GHR t1/2 was
already quite prolonged in those cells). The results of these studies are
consistent with the idea that JAK2 affects surface GHR availability at
the level of constitutive endocytosis and lysosomal degradation and
that proteasome inhibition in cells that lack JAK2 blocks the ability of
the receptor to enter this pathway. Whether proteasome inhibitor
exerts this effect by a more “global” mechanism (eg., by depleting
available cellular stores of ubiquitin by blocking turnover of
ubiquitinated proteins) vs. speciﬁcally impacting the turnover of the
GHR or other proteins involved in its constitutive downregulation is as
yet unclear. Likewise, further research will be required to deﬁnitively
discernwhether JAK2 functions in this process by inhibiting entry into
the endocytic pathway vs. promoting recycling of already endocytosed
receptors.
5. GH-induced GHR downregulation: roles of JAK2, GHR tyrosine
phosphorylation, and ubiquitination
Like many surface receptors, GHR undergoes important trafﬁcking
events in response to binding of its ligand. The net effect is substantial
GH-induced receptor downregulation, which serves to limit or alter
the receptor's signaling capacity and perhaps thereby further
emphasize the physiologic effects of pulsatile GH release from the
pituitary gland. Work as early as the 1970s–1980s and since that time
suggested that GH-induced GHR downregulation proceeds via clathrinharboring GHR and JAK2 molecules that can associate, surface GHR is downregulated at
olecules that cannot associate, GHR undergoes enhanced constitutive downregulation
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100]. As mentioned above, mutagenesis studies have pointed to a
cytoplasmic domain region of the receptor that includes the UbEmotif
as required for efﬁcient GH-induced GHR endocytosis and down-
regulation [92,94–97]. While many studies have indicated that GH
markedly augments the constitutive rate of GHR downregulation
described above, some have suggested only a modest GH-induced
increase [93,101]. Similarly, the roles of GH signaling and, in particular,
JAK2 activity, in promoting receptor downregulation have been
debated. Studies in which chemical kinase inhibitors have been
employed suggested that JAK2 kinase activation is required for GH-
induced receptor downregulation [102,103]. Like all such inhibitor
studies, potential nonspeciﬁc effects of the compounds used could
hamper interpretation. A different conclusion was drawn by Strous
and colleagues in the GHR-transfected temperature-sensitive Chinese
hamster lung ﬁbroblast system mentioned above; in this case, a
receptor with a mutated Box 1 element (which disrupts GHR–JAK2
association) was downregulated in response to GH similarly to the
wild-type GHR, suggesting to the authors that GHR degradation is
independent of signal transduction via JAK2 [104].
This question of the role of JAK2 and its activation in GH-induced
GHR downregulation compared to constitutive downregulation, was
approached recently, again using the reconstitution system described
above [105]. In cells that harbor JAK2, GH markedly enhanced GHR
degradation; however, in cells that lack JAK2, GH had no effect on
receptor degradation (which proceeded at a high level constitutively
in the absence of JAK2). Thus, in this system, GH caused receptor
downregulation in a JAK2-dependent fashion. Expression of a GHR
mutant that lacks the ability to interact with JAK2 resulted in
enhanced constitutive receptor downregulation and a loss of GH-
induced downregulation. Similarly, the ability of JAK2 to both allow
GH-induced receptor loss and to protect GHR from constitutive
degradation depended on the presence of an intact (GHR-associating)
FERM domain within JAK2. In distinction, JAK2 mutants lacking the
kinase-like and kinase domains did not mediate GH-induced GHR
downregulation, despite their ability to protect the receptor from
constitutive downregulation. A kinase-deﬁcient JAK2 mutant was also
unable to mediate GH-induced GHR downregulation, conﬁrming that
kinase activity is required. Notably, a GHR mutant in which all the
cytoplasmic tyrosine residues were changed to phenylalanines was
also resistant to GH-induced GHR downregulation; this powerful
observation indicates that tyrosine phosphorylation of the receptor
(rather than JAK2 kinase activation only) is required for GH-induced
receptor loss. Interestingly, GH-induced GHR ubiquitination was
detected in cells expressing wild-type GHR and JAK2, but not in
cells that expressed wild-type GHR and a kinase-deﬁcient JAK2 or in
those with wild-type JAK2 and the GHR mutant with all tyrosines
changed to phenylalanine, indicating that GH-induced receptor
ubiquitination depends on both JAK2 activity and the ability of the
receptor to be tyrosine phosphorylated.
Pharmacologic studies in this system showed that a lysosome
inhibitor (chloroquine) blocked GH-induced GHR downregulation in
cells harboring wild-type GHR and JAK2, consistent with previous
ﬁndings in other systems that GH ultimately causes its receptor to be
degraded in lysosomes. However, as we found for constitutive
downregulation of GHR in JAK2-deﬁcient cells (above), a proteasome
inhibitor (lactacystin) also blocked GH-induced GHR downregulation.
This is consistent with the work of Strous and colleagues (described
above) in that intact proteasome activity is needed for effective GH-
induced GHR downregulation. But, importantly, in contrast to
previous reports, the ﬁndings in this system are also consistent with
the possibility that GHR ubiquitination itself might play a role in its
downregulation.
Tyrosine phosphorylation is essential for downregulation of
various cell surface receptors. One of the best studied is the epidermal
growth factor receptor (EGFR), which autophosphorylates in responseto EGF, allowing association with ubiquitinating machinery, ubiquiti-
nation of the receptor itself, and its post-endocytic lysosomal degra-
dation [106]. For GHR, several binding partners have been shown to
associate via their SH2 domains with the tyrosine phosphorylated
intracellular domain [30,107–111]. One of them, the protein tyrosine
phosphatase, SHP-2, may contribute modestly to GH-induced GHR
downregulation [108]. More recently, it has been appreciated that the
SOCS family protein CIS (cytokine inducible SH2 domain-containing
protein), which interacts with tyrosine phosphorylated GHR [109,110]
and is likely linked to Cullin5-based E3 ubiquitin ligase complex that
can recruit proteins to the proteasome for degradation [112], promotes
GH-induced GHR internalization and thus can desensitize GH
signaling [113]. Whether CIS regulates GHR downregulation at a
level following internalization is not known. Another E3 ubiquitin
ligase, β-TrCP (β-transducin repeats-containing protein), may func-
tion in the ligand-induced ubiquitination and proteolysis of cytokine
receptor family members including interferon-α receptor 1 (IFNAR1),
prolactin receptor (PRLR) and erythropoietin receptor [114–118].
Phosphorylation of speciﬁc serine residues within the cytoplasmic
domain of these receptors allows ligand-induced association with β-
TrCP, receptor ubiquitination, and downregulation [115,117]. In the
case of IFNAR1 and the PRLR, receptor phosphorylation within the β-
TrCP-bindingmotif required the catalytic activity of the associated JAK
(TYK2 for IFNAR1 and JAK2 for PRLR) [119,120] and, like our ﬁndings
for GHR, ubiquitination of EpoR requires JAK2 activity [121].
β-TrCP has also recently been implicated in GHR downregulation
in that knockdown of this molecule retards receptor internalization
and increases its steady-state abundance [122]. Furthermore, the
GHR cytoplasmic tail and β-TrCP were shown to associate in in vitro
binding assays, intriguingly via the receptor's UbE motif, rather than
via the canonical DSG motif seen for other β-TrCP-binding proteins
and also present in the GHR [122]. Whether this novel association
and/or β-TrCP itself are the critical determinants of GH-induced
receptor downregulation remains unknown in the intact cellular
setting. Based on our data above with the GHR that cannot undergo
tyrosine phosphorylation, our view is that future studies that
identify proteins that differentially associate with a wild-type vs.
tyrosine mutated GHR in response to GH stimulation might shed
light on the reasons underlying the defective ligand-induced down-
regulation of the latter receptor and whether it is due to its inability
to be tyrosine phosphorylated, ubiquitinated, or both. This is an
interesting area that may yield substantial insight into the mechan-
isms of downregulation of GHR and, by extension, other cytokine
receptor family members.
6. Mechanistic links between ubiquitination and endocytosis:
lessons from GHR and other cytokine/hormone receptors
For the past ten years, an important role of receptor ubiquitination
in regulating the rate of their endocytosis has emerged. During this
time span, it has been demonstrated that mono-ubiquitinated cargo
receptors are recruited to the proteins containing ubiquitin-binding
domains. Accordingly, a prevalent line of thought (supported by
experiments utilizing a linear fusion of ubiquitin to the intracellular
tail of the receptor) was that such proteins link receptor cargo to the
components of endocytic and sorting machinery thereby enabling
receptor internalization and post-internalization sorting. Under this
scenario, neither polyubiquitination nor the topology of ubiquitin
chains nor the site of ubiquitin conjugation should be important for
the efﬁciency of endocytosis [123–128].
However, recent studies on mechanisms that govern internaliza-
tion of the interferon alpha receptor revealed that site-speciﬁc
polyubiquitination promotes internalization of this receptor via
exposing a linear endocytic motif within the receptor to the inter-
action with the AP2 adaptin complex which is essential for efﬁcient
internalization. The lines of this new paradigm, therefore, suggest
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linear motif within the receptor might be masked by receptor-
interacting proteins that shield such a motif from the AP2 adaptin
complex. Upon ligand addition, stimulation of a site- and topology-
speciﬁc ubiquitination of the intracellular domain of a receptor may
result in exposure of the linear motif to the adaptin complex either via
rearranging the masking protein complex or by changing the
conformation of the intracellular tail of a given receptor in a way
that enables such interaction.Whereas additionalmechanisms leading
to an exposure of a linear endocytic motif cannot be ruled out,
ubiquitination-stimulated interaction of adaptin with such a motif on
one hand and clathrin lattices on another hand should promote
efﬁcient internalization of a given cytokine/hormone receptor.
TYK2 has recently been identiﬁed as a component of this masking
complex for interferon alpha receptor (S.Y.F., unpublished data). In
cells lacking TYK2 or under the conditions where TYK2 recruitment is
impaired, the receptor undergoes very efﬁcient basal endocytosis that
is totally independent of receptor ubiquitination. Other masking
determinants that protect various endocytic motifs and, hence, limit
basal internalization of other signaling receptors to preserve a
physiological density of surface receptors should be eventually
identiﬁed. In case of GHR, although the identity of linear motifs and
masking proteins remain to be determined, the evaluation of this
scenario might be useful to understand the counterintuitive results
obtained by the Strous group on GHR.
While, in some cases, interacting proteins will been involved
(similar to the function of TYK2 for interferon alpha receptor), masking
could also be achieved by intramolecular folding of the receptor itself.
Thus, the functional role of a given endocytic determinant should
always be investigated in the context of the full-length receptor. There
might be a need to revise the interpretation of data obtained from
studies that relied on deletions of the intracellular domains as a
strategy for delineating either ubiquitination-related or linear endo-
cytic motifs of signaling receptors. Such deletions might potentially
remove not only important positive regulators of endocytosis (such as
a recognition signal for a ubiquitin ligase or a ubiquitin-acceptor site)
but also docking sequences or surfaces involved in recruitment of
masking proteins. In support of this hypothesis, the ubiquitin-
independent role of di-leucine linear endocytic motifs that emerge
in a truncated GHR has been reported [95].
As per the role of either ubiquitination or linear motifs or both in
clathrin-mediated internalization of cell surface receptors, GHR will
likely fall into the group for which cooperation between ubiquitina-
tion and linear endocytic motifs might serve as amajor mechanism for
promoting the internalization of these receptors. While a candidate
linear motif that might be important for such interaction within the
intracellular domain of GHR has been revealed [129], and GHR has
been the ﬁrst mammalian receptor for which an overall role of
ubiquitination for its endocytosis and degradation has been demon-
strated [95] and further delineated by an elegant work of the Strous
group [19,91–94,96,104,129–136], the role of GHR ubiquitination per
se (as opposed to ubiquitination of the components of endocytic
machinery) in internalization and degradation of GHR remains
controversial. The bulk of available data strongly suggest a logical
connection between GHR ubiquitination followed by its endocytosis
followed by the proteolytic turnover in the lysosomes. Furthermore,
similarly to IFNAR1 [114,137] and PRLR [116,120], β-TrCP-based E3
ubiquitin ligase interaction (via a non-canonical UbE domain instead
of the canonical phosphodegron) and Cullin1-dependent E3 ligase
activity govern the endocytosis and degradation of GHR [95].
However, the latter report also suggests that ubiquitination of GHR
itself does not largely affect the rate of GHR endocytosis. This con-
clusion is based on the observation that mutation of all of lysine
residues within the cytoplasmic tail of a truncated rabbit GHR into
arginines did not affect its endocytosis [96]. However, while ubiqui-
tination of truncated receptor (whose linear motifs might be alreadyexposed to interacting with AP2) for its internalization might be
dispensable, the same is not necessarily true for the full-length
receptor. Work of the Pellegrini group has demonstrated that IFNAR1
mutants lacking Tyk2-binding sites (but retaining phosphodegron
and, therefore, ubiquitination) undergo very efﬁcient endocytosis [71].
It remains to be seen whether abrogation of the full-length GHR
ubiquitination bymeans that do not involve its extensivemutagenesis,
which might activate alternative or downstream internalization
pathways, will not be essential for its efﬁcient endocytosis. Another
possibility is that, in the absence of lysines, ubiquitinationmight occur
on the cysteine residues. Furthermore, such ubiquitination can
stimulate endocytosis as has been demonstrated for the major histo-
compatibility complex class I molecules decorated by viral E3 ubi-
quitin ligases [138]. In all, given these relatively recent developments,
the issue of the role of GHR ubiquitination in its internalization, post-
internalization sorting and lysosomal degradation might merit being
revisited.
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